AR 20
Alternative Names: AR-20Latest Information Update: 15 Feb 2022
Price :
$50 *
At a glance
- Originator Arbor Pharmaceuticals
- Class Neuropsychotherapeutics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Mental disorders
Most Recent Events
- 15 Feb 2022 Discontinued - Phase-III for Mental disorders in USA (unspecified route) (Azurity Pharmaceuticals/Arbor pharmaceuticals pipeline, February 2022)
- 25 Jul 2016 Phase-III clinical trials in Mental disorders in USA (unspecified route)
- 20 Apr 2016 Phase-II clinical trials in Mental disorders in USA (unspecified route)